Gazo Biotech Lands $36.7 Million In Series A Financing

According to VCBeat, Gazo Biotech just received around 36.7 million dollars in Series A financing, this round of financing was led by Beizeng Asset, Efung Capital, Haige Capital and a few other institutions. The funds will be used for the construction of new plants, products R&D and clinical trials.

Gazo Biotech was founded in 2001. It mainly focuses on R&D and the production of vaccines, since vaccines can save a lot of money compare to regular treatment. Gazo Biotech has many production pipelines such as meningitis, rabies, rubella and chickenpox.

At present, many domestic vaccine varieties are in short supply, such as influenza vaccine. The supply and demand ratio in 2018 is about 1:3. On the other hand, Gazo Biotech has a great team with a strong management system, this could ensure a better profit potential in the future.

Beizeng Asset is an investment and asset management company in China.

Efung Investment Management is an institution that invests in professional biomedical industries.

Haige Capital is a Chinese investment company that focuses on the field of health care.